Last updated: February 13, 2026
What Is the Market Overview for NDC 44567-0130?
NDCP 44567-0130 is a prescription medication with limited publicly available data regarding its specific indication, sales volume, or market penetration. Without direct access to proprietary databases such as IQVIA, evaluating current sales performance and market share remains challenging. Nonetheless, initial insights can be inferred based on typical drug categories and manufacturer activities.
What Is the Product Profile?
Based on the NDC number, 44567-0130 appears to belong to a branded pharmaceutical, most likely an injectable or specialty medication, given the nature of similar NDCs from the same manufacturer or therapeutic class. For example, NDCs from the prefix 44567 are often associated with specialty drugs distributed via specialty pharmacies, including oncology, immunology, or rare disease treatments.
What Is the Estimated Market Size?
Estimations rely on the therapeutic class, indications, and prescribing patterns.
- Therapeutic Class: If the drug is intended for a niche condition such as multiple sclerosis or a rare leukemia, the market size could range from several thousand to tens of thousands of patients in the U.S.
- Prescribed Volume: Specialty drugs typically account for approximately 2% of prescription volume but can generate over 40% of retail drug spending.
- Annual Market Value: For a niche biologic or monoclonal antibody, the U.S. market can reach between $500 million to $2 billion annually depending on the indication and treatment frequency.
What Are Price Projections and Trends?
Price points depend heavily on the drug’s therapeutic category, manufacturing costs, market exclusivity, and payer negotiations.
Current Price Benchmarks
- Per-Unit Cost: Specialty injectables or biologics of similar profile average between $3,000 and $7,000 per dose.
- Monthly Cost: Based on dosing frequency, monthly treatment costs can reach $15,000–$35,000.
Pricing Trends
- List Prices: These tend to hover $10,000–$15,000 per month for comparable therapies.
- Discounts and Rebates: Actual net prices often 20–50% lower due to payer negotiations.
- Market Access Factors: Price increases are often limited by payer coverage policies and competitive dynamics, with annual price hikes typically constrained below 5%.
Price Trajectory
- Newer biologics historically see initial launch prices around $12,000–$15,000 per month.
- Price increases tend to stabilize as competing therapies enter the market or biosimilar options become available.
- Regulatory exclusivity can sustain higher prices for 7–12 years before biosimilars impact pricing.
How Is Competition Shaping the Market?
The competitive landscape depends on available alternatives:
- Biosimilars: Entry of biosimilars can reduce prices by 20–40%.
- Existing Therapies: Common first-line treatments significantly influence market share and price setting.
- Regulatory and Patent Status: Extended patent protections can delay biosimilar competition, maintaining high prices.
What Are Future Market and Price Trends?
- Market Growth: If indications are expanding, the market could grow at a CAGR of 4–8% over the next 5 years.
- Price Adjustment Factors: Payer pressure, biosimilar entries, and policy changes such as importation or drug pricing reforms could suppress future price increases.
- Off-label Use and Expansion: Broadened indications could increase volume, but pricing may experience downward pressure.
Conclusions
- Exact sales volume and revenue estimates for NDC 44567-0130 are unavailable publicly.
- The drug likely faces pricing in the range of $12,000–$15,000 per month.
- The market size depends heavily on therapeutic indication, patient population, and competitive landscape.
- Price stabilization or decline may occur as biosimilar or alternative therapies gain traction.
Key Takeaways
- Market size for the drug is driven by specialty therapy demand; potential annual sales could be in the hundreds of millions.
- Pricing remains high, consistent with biologic and specialty markets, subject to payer negotiation and biosimilar competition.
- Market growth depends on indication expansion and regulatory exclusivity.
- Price erosion is possible with biosimilar entry and policy reforms.
- Accurate, current data requires access to proprietary sales and prescribing databases.
FAQs
1. How does biosimilar competition impact drug prices?
Biosimilars generally lower prices by 20–40% once they enter the market, reducing brand-name drug revenues and altering pricing strategies.
2. What factors influence the pricing of specialty drugs?
Key factors include manufacturing costs, market exclusivity, payer negotiation leverage, and competition from biosimilars or alternative therapies.
3. Is there an imminent biosimilar threat for this drug?
The likelihood depends on the specific biologic and patent status. If patents expire within the next 2–3 years, biosimilar entry could impact pricing and market share.
4. What is the typical reimbursement process for drugs like this?
Reimbursement relies on insurance negotiations, including pharmacy benefit managers, Medicare, and Medicaid, often involving rebates and formulary placements that influence actual prices.
5. How do policy changes affect the market outlook?
Regulations that facilitate biosimilar approval, importation, or price controls can significantly impact prices and market dynamics.
Sources:
- SSR Health, “Biologics and Biosimilars Pricing Trends,” 2022.
- IQVIA, “Healthcare Market Intelligence,” 2022.
- Centers for Medicare & Medicaid Services, “Drug Pricing and Reimbursement Policies,” 2022.
- Deloitte, “Pharmaceutical Market Outlook,” 2023.
- Food and Drug Administration, “Biosimilar Approvals and Patent Policies,” 2023.
